Upstream Bio Reports Widened Q1 Net Loss to $40.6M Amid Increased R&D, Confirms Cash Runway Through 2027

summarizeSummary

Upstream Bio reported a larger net loss of $40.6 million for Q1 2026 due to increased R&D for its verekitug program, but confirmed its cash runway extends through 2027. The company has a $150 million ATM program in place, though no shares have been sold yet.

check_boxKey Events

• Net Loss Widens Significantly

  The net loss for Q1 2026 increased to $40.6 million, up from $27.3 million in Q1 2025, reflecting higher operational costs.

• R&D Expenses Jump

  Research and development expenses rose by $10.8 million to $36.6 million, driven by progress in COPD and asthma clinical trials and Phase 3 planning.

• Cash Position and Runway

  Cash, cash equivalents, and short-term investments stood at $294.6 million as of March 31, 2026. The company projects this capital will fund operations through 2027.

• ATM Program Established

  An At-The-Market (ATM) equity offering program for up to $150 million was established on March 26, 2026, providing a financing option, but no shares have been sold to date.

auto_awesomeAnalysis

Upstream Bio, a clinical-stage biotechnology company, reported a net loss of $40.6 million for Q1 2026, a significant increase from $27.3 million in Q1 2025. This widening loss is primarily driven by a substantial increase in research and development (R&D) expenses, which rose by $10.8 million to $36.6 million. The increased R&D spend is attributed to the continued advancement of its verekitug program, specifically the Phase 2 clinical trial for COPD, the Phase 2 LTE study for severe asthma, and planning activities for Phase 3 trials in both severe asthma and CRSwNP. Despite the increased cash burn from operations, which reached $47.9 million for the quarter, the company maintains a cash, cash equivalents, and short-term investments balance of $294.6 million as of March 31, 2026. Management reaffirms its belief that existing capital is sufficient to fund operations through 2027. The company also noted the establishment of a $150 million At-The-Market (ATM) equity offering program on March 26, 2026, though no shares have been sold under this program to date. New risk factors were highlighted, including potential impacts from the BIOSECURE Act on manufacturing relationships and the evolving regulatory landscape for artificial intelligence.